Advertisement

Journal of Neuroimmune Pharmacology

, Volume 14, Issue 4, pp 697–708 | Cite as

Beta1- and Beta2-Adrenoceptors Expression Patterns in Human Non-small Cell Lung Cancer: Relationship with Cancer Histology

  • Marisa CoelhoEmail author
  • Andrea Imperatori
  • Anna Maria Chiaravalli
  • Francesca Franzi
  • Massimo Castiglioni
  • Emanuela Rasini
  • Alessandra Luini
  • Massimiliano Legnaro
  • Franca Marino
  • Laura Ribeiro
  • Marco Cosentino
ORIGINAL ARTICLE
  • 84 Downloads

Abstract

Assessment of Beta-AR protein expression on tumour tissues might be a plausible strategy to select cancer patients who can benefit from Beta-blockers therapy. The aim of this study is to evaluate the differences between resected tissue specimens from primary lung cancer (adenocarcinoma (ADC) and squamous cell carcinoma (SCC)) in terms of expression pattern of Beta1- and Beta2-AR in both tumour and adjacent surrounding non-tumour tissue. This retrospective study was based on the analysis of 80 patients with histologically confirmed diagnosis of primary Non-Small Cell Lung Cancer (NSCLC) who received surgical treatment. The cases were carefully selected in order to obtain the most homogeneous sample in terms of histologic subtype (40 ADCs and 40 SCCs) and clinical stage (10 each). Beta1- and Beta2-AR expression was determined by immunohistochemistry and the staining evaluated by semi-quantitative scoring using the H-score method. In our NSCLC series, Beta1- and Beta2-AR are differentially expressed. Beta1-AR expression is present at low levels in both SCC and ADC. Likewise, when compared with the matched surrounding non-tumour tissues, Beta1-AR expression level was significantly lower in both histologic subtypes. Conversely, Beta2-AR is highly expressed in both histologic subtypes, but clearly highly expressed in ADC when compared with SCC and with their matched surrounding non-tumour tissue. Overall, this clinicopathological study highlights the differential expression of Beta1- and Beta2-AR in ADC and SCC. Repurposing non-selective Beta-blockers in oncologic setting might be a suitable therapeutic strategy for lung ADC.

Graphical abstract

Keywords

Beta-adrenoceptors Non-small cell lung cancer Clinicopathological study Immunohistochemistry 

Notes

Acknowledgements

The authors gratefully acknowledge all the staff from Unit of Pathology, Department of Medicine and Surgery (University of Insubria), particularly, Professor Fausto Sessa for his availability and Daniele Sabatino for kindly helping us capturing the IHC photos. The authors also thank the staff of Department of Medicine and Surgery, Center for Thoracic Surgery, (University of Insubria), especially Professor Lorenzo Dominioni. Marisa Coelho is grateful to the PhD Course in Clinical and Experimental Medicine and Medical humanities, University of Insubria, Italy for the PhD scholarship.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Ethics Approval and Consent to Participate

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee. Permission was obtained from the local ethics committee (Ospedale del Circolo - Varese) for this retrospective analysis. For this type of study formal consent is not required. All data were recorded and analysed anonymously.

Supplementary material

11481_2019_9879_MOESM1_ESM.docx (26 kb)
ESM 1 (DOCX 25 kb)
11481_2019_9879_MOESM2_ESM.docx (24 kb)
ESM 2 (DOCX 23 kb)
11481_2019_9879_MOESM3_ESM.docx (26 kb)
ESM 3 (DOCX 25 kb)

References

  1. Al-wadei HAN, Al-wadei MH, Schuller HM (2012) Cooperative regulation of non-small cell lung carcinoma by nicotinic and Beta-adrenergic receptors : a novel target for intervention. PLoS One 7:e29915.  https://doi.org/10.1371/journal.pone.0029915 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Billington C, Penn RB, Hall IP (2017) β2-agonists. Handb Exp Pharmacol 237:23–40.  https://doi.org/10.1007/164 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bossard F, Silantieff E, Lavazais-Blancou E et al (2011) β1, β2, and β3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis. Am J Respir Cell Mol Biol 44:91–98.  https://doi.org/10.1165/rcmb.2009-0372OC CrossRefPubMedGoogle Scholar
  4. Bravo-Calderón DM, Oliveira DT, Marana AN et al (2012) Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma. Cancer Biomark 10:51–59.  https://doi.org/10.3233/CBM-2012-0228 CrossRefGoogle Scholar
  5. Chen D, Xing W, Hong J et al (2012) The Beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol 19:3556–3565.  https://doi.org/10.1245/s10434-012-2396-1 CrossRefPubMedGoogle Scholar
  6. Chisholm KM, Chang KW, Truong MT et al (2012) β-Adrenergic receptor expression in vascular tumors. Mod Pathol 25:1446–1451.  https://doi.org/10.1038/modpathol.2012.108 CrossRefPubMedGoogle Scholar
  7. Coelho M, Silva CS, Brandão D et al (2017) β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol 143:275–291.  https://doi.org/10.1007/s00432-016-2278-1 CrossRefPubMedGoogle Scholar
  8. Coelho M, Imperatori A, Chiaravalli AM, et al (2018) β-blockers in NSCLC: β1/β2-AR selectivity matters but it might be not enough. In: Sci. Transl. Med. http://stm.sciencemag.org/content/9/415/eaao4307
  9. Cole SW, Sood AK (2012) Molecular pathways: Beta-adrenergic signaling in Cancer. Clin Cancer Res 18:1201–1206.  https://doi.org/10.1158/1078-0432.CCR-11-0641 CrossRefPubMedGoogle Scholar
  10. Cole SW, Nagaraja AS, Lutgendorf SK et al (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer 15:563–572.  https://doi.org/10.1038/nrc3978 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Cosentino M, Marino F, Ferrari M et al (2007) Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignanTM) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells. Pharmacol Res 56:140–147.  https://doi.org/10.1016/j.phrs.2007.05.001 CrossRefPubMedGoogle Scholar
  12. Daly CJ, Mcgrath JC (2011) Previously unsuspected widespread cellular and tissue distribution of b-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci 32:219–226.  https://doi.org/10.1016/j.tips.2011.02.008 CrossRefPubMedGoogle Scholar
  13. Eng JW-L, Kokolus KM, Reed CB et al (2014) A nervous tumor microenvironment: the impact of adrenergic stress on Cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother 63:1115–1128.  https://doi.org/10.3851/IMP2701.Changes CrossRefPubMedPubMedCentralGoogle Scholar
  14. Faruki H, Mayhew GM, Serody JS et al (2017) Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol 12:943–953.  https://doi.org/10.1016/j.jtho.2017.03.010 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Hu P, He J, Liu S et al (2016) β2-adrenergic receptor activation promotes the proliferation of A549 lung cancer cells via the ERK1/2 / CREB pathway. Oncol Rep 36:1757–1763.  https://doi.org/10.3892/or.2016.4966 CrossRefPubMedGoogle Scholar
  16. Ji Y, Chen S, Xiao X et al (2012) β-blockers: a novel class of antitumor agents. OncoTargets Ter 5:391–401CrossRefGoogle Scholar
  17. Laag E, Majidi M, Cekanova M et al (2006) NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 119:1547–1552.  https://doi.org/10.1002/ijc.21987 CrossRefPubMedGoogle Scholar
  18. Liu D, Deng Q, Sun L et al (2015) A Her2-let-7-beta2-AR circuit affects prognosis in patients with Her2-positive breast cancer. BMC Cancer 15:1–10.  https://doi.org/10.1186/s12885-015-1869-6 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lou Y, Peng WJ, Cao Y et al (2013) The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol 78:44–57.  https://doi.org/10.1111/bcp.12235 CrossRefPubMedCentralGoogle Scholar
  20. Nagaraja AS, Sadaoui NC, Lutgendorf SK et al (2013) Beta blockers : a new role in chemotherapy. Expert Opin Investig Drugs 22:1359–1363.  https://doi.org/10.1517/13543784.2013.825250.Beta CrossRefPubMedPubMedCentralGoogle Scholar
  21. Nilsson MB, Sun H, Diao L et al (2017) Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9:eaao4307.  https://doi.org/10.1126/scitranslmed.aao4307 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27.  https://doi.org/10.1093/annonc/mdw326 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Pantziarka P, Bouche G, Meheus L et al (2016) Repurposing drugs in oncology (ReDO)-propranolol as an anti-cancer agent. Ecancermedicalscience 10:1–32.  https://doi.org/10.3332/ecancer.2014.443 CrossRefGoogle Scholar
  24. Quốc Lu’o’ng KV, Nguyễn LTH (2012) The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res 4:431–445.  https://doi.org/10.2147/CMAR.S39153 CrossRefPubMedPubMedCentralGoogle Scholar
  25. Rains SL, Amaya CN, Bryan BA (2017) Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 4:95–105.  https://doi.org/10.18632/oncoscience.357 CrossRefPubMedPubMedCentralGoogle Scholar
  26. Ramberg H, Eide T, Krobert KA et al (2008) Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 68:1133–1142.  https://doi.org/10.1002/pros.20778 CrossRefPubMedGoogle Scholar
  27. Raponi M, Zhang Y, Yu J et al (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:7466–7472.  https://doi.org/10.1158/0008-5472.CAN-06-1191 CrossRefPubMedGoogle Scholar
  28. Scanzano A, Schembri L, Rasini E et al (2015) Adrenergic modulation of migration, CD11b and CD18 expression, ROS and interleukin-8 production by human polymorphonuclear leukocytes. Inflamm Res 64:127–135.  https://doi.org/10.1007/s00011-014-0791-8 CrossRefPubMedGoogle Scholar
  29. Schuller HM (2010) Beta-adrenergic signaling , a novel target for cancer therapy ? Oncotarget 1:466–469CrossRefGoogle Scholar
  30. Schuller HM, Cekanova M (2005) NNK-induced hamster lung adenocarcinomas over-express β2- adrenergic and EGFR signaling pathways. Lung Cancer 49:35–45.  https://doi.org/10.1016/j.lungcan.2004.12.012 CrossRefPubMedGoogle Scholar
  31. Schuller HM, Cole B (1989) Regulation of cell proliferation by β-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis 10:1753–1755CrossRefGoogle Scholar
  32. Schuller HM, Tithof PK, Williams M, Plummer H (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59:4510–4515PubMedGoogle Scholar
  33. Spagnuolo P, Rasini E, Luini A et al (2014) Isoflavone content and estrogenic activity of different batches of red clover (Trifolium pratense L.) extracts: an in vitro study in MCF-7 cells. Fitoterapia 94:62–69.  https://doi.org/10.1016/j.fitote.2014.01.027 CrossRefPubMedGoogle Scholar
  34. Takahashi K, Kaira K, Shimizu A et al (2016) Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumor Biol 37:13885–13892.  https://doi.org/10.1007/s13277-016-5139-2 CrossRefGoogle Scholar
  35. Vogel C, Marcotte EM (2013) Insights into regulation of protein abundance from proteomics and transcriptomis analyses. Nat Rev Genet 13:227–232.  https://doi.org/10.1038/nrg3185.Insights CrossRefGoogle Scholar
  36. Yang P (2009) Epidemiology of lung Cancer prognosis: quantity and quality of life. Methods Mol Biol 471:469–486.  https://doi.org/10.1007/978-1-60327-492-0 CrossRefPubMedPubMedCentralGoogle Scholar
  37. Yazawa T, Kaira K, Shimizu K et al (2016a) Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res 8:5059–5070PubMedPubMedCentralGoogle Scholar
  38. Yazawa T, Kaira K, Shimizu K et al (2016b) Prognostic significance of β2-adrenergic receptor expression in malignant melanoma. Tumor Biol 37:5971–5978.  https://doi.org/10.1007/s13277-015-4420-0 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Marisa Coelho
    • 1
    • 2
    • 3
    Email author
  • Andrea Imperatori
    • 4
  • Anna Maria Chiaravalli
    • 5
  • Francesca Franzi
    • 5
  • Massimo Castiglioni
    • 4
  • Emanuela Rasini
    • 3
  • Alessandra Luini
    • 3
  • Massimiliano Legnaro
    • 3
  • Franca Marino
    • 3
  • Laura Ribeiro
    • 1
    • 2
  • Marco Cosentino
    • 3
  1. 1.Department of Biomedicine, Unit of Biochemistry, Faculty of MedicineUniversity of PortoPortoPortugal
  2. 2.I3S - Instituto de Investigação e Inovação em SaúdeUniversity of PortoPortoPortugal
  3. 3.Center of Research in Medical PharmacologyUniversity of InsubriaVareseItaly
  4. 4.Center for Thoracic Surgery, Department of Medicine and Surgery, ASST Sette LaghiUniversity of InsubriaVareseItaly
  5. 5.Unit of Pathology, Department of Medicine and Surgery, ASST Sette LaghiUniversity of InsubriaVareseItaly

Personalised recommendations